NVCT net incomeQ3 2026-$30.07M
NVCT net income was -$30.07M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$7.46M a year earlier. For the full fiscal 2025 it was -$26.44M, compared with -$19.00M in fiscal 2024.
Nuvectis Pharma Inc. (NVCT) financials
For the twelve months ended Sep 30, 2026, Nuvectis Pharma Inc. reported -$50.45M of net income.
- Net income, TTM
- -$50.45M
- EPS, diluted, TTM
- -$1.89
- Cash
- $140.71M
- Market cap
- $722.9M
FY2021FY2025
NVCT revenue and earnings growth
NVCT EPSQ3 2026-$1.02
NVCT diluted EPS was -$1.02 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.44 a year earlier. For the full fiscal 2025 it was -$1.32, compared with -$1.11 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Research and development | $18.15M | $12.92M | $15.38M | $13.23M | $9.54M |
| Selling, general and admin | $9.42M | $6.93M | $7.52M | $6.01M | $3.35M |
| Operating income | -$27.57M | -$19.85M | -$22.90M | -$19.23M | -$12.89M |
| Net income | -$26.44M | -$19.00M | -$22.26M | -$19.09M | -$12.89M |
| EPS, basic | -$1.32 | -$1.11 | -$1.43 | -$1.51 | -$3.02 |
| EPS, diluted | -$1.32 | -$1.11 | -$1.43 | -$1.51 | -$3.02 |
| Diluted shares | 21.8M | 17.1M | 15.6M | 12.7M | 4.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $31.63M | $18.53M | $19.13M | $19.99M | $5.74M |
| Current assets | $31.71M | $18.61M | $19.18M | $20.41M | $5.83M |
| Total assets | $31.71M | $18.61M | $19.18M | $20.41M | $6.66M |
| Current liabilities | $13.30M | $8.89M | $6.98M | $6.19M | $2.42M |
| Total liabilities | $13.30M | $8.89M | $6.98M | $6.19M | $2.42M |
| Shareholders' equity | $18.41M | $9.71M | $12.20M | $14.22M | -$11.01M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$16.01M | -$12.25M | -$15.95M | -$13.56M | -$9.50M |
| Investing cash flow | - | $0 | $0 | $0 | - |
| Financing cash flow | $29.11M | $11.65M | $15.09M | $27.81M | $15.25M |
| Stock-based compensation | $6.03M | $4.86M | $4.71M | $1.71M | $1.89M |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $27.37M | $4.68M | $4.11M | $5.09M | $5.77M | $3.61M | $3.68M | $4.50M | $2.82M | $2.94M | $2.66M | $4.26M |
| Selling, general and admin | $3.68M | $2.51M | $2.15M | $2.53M | $2.02M | $2.98M | $1.89M | $1.95M | $1.54M | $1.70M | $1.74M | $2.60M |
| Operating income | -$31.05M | -$7.20M | -$6.26M | -$7.62M | -$7.79M | -$6.59M | -$5.57M | -$6.45M | -$4.36M | -$4.64M | -$4.40M | -$6.87M |
| Net income | -$30.07M | -$7.02M | -$6.05M | -$7.31M | -$7.46M | -$6.33M | -$5.33M | -$6.25M | -$4.15M | -$4.43M | -$4.17M | -$6.62M |
| EPS, basic | -$1.02 | -$0.30 | -$0.26 | -$0.31 | -$0.44 | -$0.30 | -$0.27 | -$0.36 | -$0.24 | -$0.26 | -$0.25 | -$0.41 |
| EPS, diluted | -$1.02 | -$0.30 | -$0.26 | -$0.31 | -$0.44 | -$0.30 | -$0.27 | -$0.36 | -$0.24 | -$0.26 | -$0.25 | -$0.41 |
| Diluted shares | 29.5M | 23.5M | 23.4M | - | 22.7M | 21.4M | 19.9M | - | 17.2M | 16.9M | 16.6M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $140.71M | $22.16M | $25.13M | $31.63M | $35.44M | $26.79M | $29.86M | $18.53M | $17.17M | $18.12M | $19.46M | $19.13M |
| Current assets | $140.84M | $22.38M | $25.40M | $31.71M | $35.59M | $27.01M | $30.15M | $18.61M | $17.31M | $18.30M | $19.71M | $19.18M |
| Total assets | $140.84M | $22.38M | $25.40M | $31.71M | $35.59M | $27.01M | $30.15M | $18.61M | $17.31M | $18.30M | $19.71M | $19.18M |
| Current liabilities | $14.19M | $13.29M | $11.18M | $13.30M | $11.58M | $10.13M | $9.19M | $8.89M | $6.32M | $5.77M | $5.69M | $6.98M |
| Total liabilities | $14.19M | $13.29M | $11.18M | $13.30M | $11.58M | $10.13M | $9.19M | $8.89M | $6.32M | $5.77M | $5.69M | $6.98M |
| Shareholders' equity | $126.65M | $9.08M | $14.22M | $18.41M | $24.01M | $16.87M | $20.95M | $9.71M | $10.99M | $12.53M | $14.02M | $12.20M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.28M | -$4.53M | -$6.51M | -$3.97M | -$4.49M | -$3.37M | -$4.17M | -$2.46M | -$2.40M | -$3.02M | -$4.36M | -$3.85M |
| Investing cash flow | - | - | $0 | - | - | - | $0 | - | - | - | $0 | - |
| Financing cash flow | $143.82M | $1.56M | $7.0K | $166.0K | $13.14M | $296.0K | $15.51M | $3.83M | $1.46M | $1.67M | $4.70M | $917.0K |
| Stock-based compensation | $2.42M | $1.71M | $1.85M | $1.48M | $1.46M | $1.73M | $1.37M | $1.14M | $1.16M | $1.26M | $1.30M | $1.22M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 9.92 | 1.68 | 2.27 | 2.38 | 3.07 | 2.66 | 3.28 | 2.09 | 2.74 | 3.17 | 3.46 | 2.75 |
Source: XBRL data Nuvectis Pharma Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
NVCT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NVCT | - | - | -$50.45M | - | $722.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
NVCT FAQ
5 questionsIs NVCT profitable?
No. Nuvectis Pharma Inc. reported a net loss of $50.45M for the twelve months ended Sep 30, 2026.How much cash and debt does NVCT have?
Nuvectis Pharma Inc. reported $140.71M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is NVCT earnings per share?
Diluted earnings per share were -$1.89 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did NVCT last report financial results?
The latest statements here come from Nuvectis Pharma Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.Where does this NVCT financial data come from?
Quantisnow builds these statements from the structured XBRL data Nuvectis Pharma Inc. files with the SEC. It is provided for information only and is not investment advice.